{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=PT003",
    "query": {
      "intervention": "PT003"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 16,
    "total_pages": 2,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=PT003&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-05T02:27:59.693Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01854658",
      "title": "Multi-Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD (PINNACLE 2)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chronic Obstructive Pulmonary Disease (COPD)"
      ],
      "interventions": [
        {
          "name": "GFF MDI (PT003)",
          "type": "DRUG"
        },
        {
          "name": "GP MDI (PT001)",
          "type": "DRUG"
        },
        {
          "name": "FF MDI (PT005)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pearl Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "40 Years to 80 Years"
      },
      "enrollment_count": 1615,
      "start_date": "2013-07",
      "completion_date": "2015-03",
      "has_results": true,
      "last_update_posted_date": "2017-03-28",
      "last_synced_at": "2026-09-05T02:27:59.693Z",
      "location_count": 113,
      "location_summary": "Birmingham, Alabama • Florence, Alabama • Jasper, Alabama + 110 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Florence",
          "state": "Alabama"
        },
        {
          "city": "Jasper",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Fullerton",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01854658"
    },
    {
      "nct_id": "NCT02497001",
      "title": "A Randomized, Double-Blind, Parallel-Group, 24-Week, Chronic-Dosing, Multi-Center Study to Assess the Efficacy and Safety of PT010, PT003, and PT009 Compared With Symbicort® Turbuhaler® (Kronos)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "COPD"
      ],
      "interventions": [
        {
          "name": "BGF MDI 320/14.4/9.6 μg",
          "type": "DRUG"
        },
        {
          "name": "GFF MDI (PT003) 14.4/9.6 μg",
          "type": "DRUG"
        },
        {
          "name": "BFF MDI (PT009) 320/9.6 μg",
          "type": "DRUG"
        },
        {
          "name": "Symbicort® Turbuhaler® (TBH) Inhalation Powder",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pearl Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "40 Years to 80 Years"
      },
      "enrollment_count": 1902,
      "start_date": "2015-08-10",
      "completion_date": "2018-01-05",
      "has_results": true,
      "last_update_posted_date": "2020-12-24",
      "last_synced_at": "2026-09-05T02:27:59.693Z",
      "location_count": 63,
      "location_summary": "Andalusia, Alabama • Jasper, Alabama • Peoria, Arizona + 54 more",
      "locations": [
        {
          "city": "Andalusia",
          "state": "Alabama"
        },
        {
          "city": "Jasper",
          "state": "Alabama"
        },
        {
          "city": "Peoria",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Fullerton",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02497001"
    },
    {
      "nct_id": "NCT01854645",
      "title": "Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chronic Obstructive Pulmonary Disease"
      ],
      "interventions": [
        {
          "name": "GFF MDI",
          "type": "DRUG"
        },
        {
          "name": "GP MDI",
          "type": "DRUG"
        },
        {
          "name": "FF MDI",
          "type": "DRUG"
        },
        {
          "name": "Open-label tiotropium bromide inhalation powder (Spiriva® Handihaler®)",
          "type": "DRUG"
        },
        {
          "name": "Placebo MDI",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pearl Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "40 Years to 80 Years"
      },
      "enrollment_count": 2103,
      "start_date": "2013-05",
      "completion_date": "2015-02",
      "has_results": true,
      "last_update_posted_date": "2017-03-28",
      "last_synced_at": "2026-09-05T02:27:59.693Z",
      "location_count": 121,
      "location_summary": "Andalusia, Alabama • Anniston, Alabama • Athens, Alabama + 118 more",
      "locations": [
        {
          "city": "Andalusia",
          "state": "Alabama"
        },
        {
          "city": "Anniston",
          "state": "Alabama"
        },
        {
          "city": "Athens",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01854645"
    },
    {
      "nct_id": "NCT02536508",
      "title": "Study to Assess the Safety and Tolerability of PT010, PT009 and PT003 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "COPD"
      ],
      "interventions": [
        {
          "name": "BGF MDI 320/14.4/9.6 μg",
          "type": "DRUG"
        },
        {
          "name": "GFF MDI 14.4/9.6 μg",
          "type": "DRUG"
        },
        {
          "name": "BFF MDI 320/9.6 μg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pearl Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "40 Years to 80 Years"
      },
      "enrollment_count": 627,
      "start_date": "2015-08-10",
      "completion_date": "2017-09-12",
      "has_results": true,
      "last_update_posted_date": "2021-02-26",
      "last_synced_at": "2026-09-05T02:27:59.693Z",
      "location_count": 64,
      "location_summary": "Dothan, Alabama • Jasper, Alabama • Peoria, Arizona + 56 more",
      "locations": [
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Jasper",
          "state": "Alabama"
        },
        {
          "city": "Peoria",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Fullerton",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02536508"
    },
    {
      "nct_id": "NCT01349816",
      "title": "PT003 MDI Dose Confirmation Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Obstructive Pulmonary Disease"
      ],
      "interventions": [
        {
          "name": "PT003",
          "type": "DRUG"
        },
        {
          "name": "PT001",
          "type": "DRUG"
        },
        {
          "name": "PT005",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pearl Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "40 Years to 80 Years"
      },
      "enrollment_count": 185,
      "start_date": "2011-06",
      "completion_date": "2011-11",
      "has_results": true,
      "last_update_posted_date": "2017-04-27",
      "last_synced_at": "2026-09-05T02:27:59.693Z",
      "location_count": 13,
      "location_summary": "Rancho Mirage, California • Colorado Springs, Colorado • Waterbury, Connecticut + 10 more",
      "locations": [
        {
          "city": "Rancho Mirage",
          "state": "California"
        },
        {
          "city": "Colorado Springs",
          "state": "Colorado"
        },
        {
          "city": "Waterbury",
          "state": "Connecticut"
        },
        {
          "city": "Clearwater",
          "state": "Florida"
        },
        {
          "city": "Pensacola",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01349816"
    },
    {
      "nct_id": "NCT02454959",
      "title": "Crossover Study to Assess the Efficacy of PT003 With and Without a Valved Holding Chamber in Subjects With Moderate to Severe COPD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "COPD"
      ],
      "interventions": [
        {
          "name": "GFF MDI (PT003) with Aerochamber",
          "type": "DEVICE"
        },
        {
          "name": "GFF MDI (PT003) without Aerochamber",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Pearl Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "40 Years to 80 Years"
      },
      "enrollment_count": 80,
      "start_date": "2015-05-01",
      "completion_date": "2016-03-25",
      "has_results": true,
      "last_update_posted_date": "2017-04-19",
      "last_synced_at": "2026-09-05T02:27:59.693Z",
      "location_count": 6,
      "location_summary": "Clearwater, Florida • Tampa, Florida • Winter Park, Florida + 3 more",
      "locations": [
        {
          "city": "Clearwater",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Winter Park",
          "state": "Florida"
        },
        {
          "city": "Charlotte",
          "state": "North Carolina"
        },
        {
          "city": "Winston-Salem",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02454959"
    },
    {
      "nct_id": "NCT02196714",
      "title": "PK Study of PT003 and PT001 in Japanese Healthy Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "COPD"
      ],
      "interventions": [
        {
          "name": "Glycopyrronium and Formoterol Fumarate (GFF) Dose 1",
          "type": "DRUG"
        },
        {
          "name": "Glycopyrronium and Formoterol Fumarate (GFF) Dose 2",
          "type": "DRUG"
        },
        {
          "name": "Glycopyrronium (GP) Dose 1",
          "type": "DRUG"
        },
        {
          "name": "Glycopyrronium (GP) Dose 2",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pearl Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 24,
      "start_date": "2014-07",
      "completion_date": null,
      "has_results": true,
      "last_update_posted_date": "2017-04-26",
      "last_synced_at": "2026-09-05T02:27:59.693Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02196714"
    },
    {
      "nct_id": "NCT02268396",
      "title": "Glycopyrronium and Formoterol Fumarate (GFF) Metered Dose Inhaler (MDI) Dose Indicator Study in Adults With Moderate to Very Severe COPD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "COPD"
      ],
      "interventions": [
        {
          "name": "Glycopyrronium and Formoterol Fumarate Metered-dose Inhaler",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pearl Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "40 Years to 80 Years"
      },
      "enrollment_count": 138,
      "start_date": "2014-11",
      "completion_date": "2015-05",
      "has_results": true,
      "last_update_posted_date": "2016-12-23",
      "last_synced_at": "2026-09-05T02:27:59.693Z",
      "location_count": 10,
      "location_summary": "Clearwater, Florida • Tampa, Florida • Winter Park, Florida + 7 more",
      "locations": [
        {
          "city": "Clearwater",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Winter Park",
          "state": "Florida"
        },
        {
          "city": "Charlotte",
          "state": "North Carolina"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02268396"
    },
    {
      "nct_id": "NCT01587079",
      "title": "Glycopyrrolate/Formoterol Fumarate MDI Compared With Spiriva® as An Active Control in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Obstructive Pulmonary Disease"
      ],
      "interventions": [
        {
          "name": "PT003",
          "type": "DRUG"
        },
        {
          "name": "PT001",
          "type": "DRUG"
        },
        {
          "name": "PT005",
          "type": "DRUG"
        },
        {
          "name": "Tiotropium inhalation powder",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pearl Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "40 Years to 80 Years"
      },
      "enrollment_count": 159,
      "start_date": "2012-04",
      "completion_date": "2012-10",
      "has_results": true,
      "last_update_posted_date": "2016-06-30",
      "last_synced_at": "2026-09-05T02:27:59.693Z",
      "location_count": 19,
      "location_summary": "Glendale, Arizona • Rancho Mirage, California • Waterbury, Connecticut + 14 more",
      "locations": [
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Rancho Mirage",
          "state": "California"
        },
        {
          "city": "Waterbury",
          "state": "Connecticut"
        },
        {
          "city": "Clearwater",
          "state": "Florida"
        },
        {
          "city": "Clearwater",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01587079"
    },
    {
      "nct_id": "NCT01349803",
      "title": "PT003 MDI Cardiovascular Safety Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Obstructive Pulmonary Disease"
      ],
      "interventions": [
        {
          "name": "PT005 MDI",
          "type": "DRUG"
        },
        {
          "name": "PT001 MDI",
          "type": "DRUG"
        },
        {
          "name": "PT003 MDI",
          "type": "DRUG"
        },
        {
          "name": "Formoterol Fumarate 12 μg (Foradil® Aerolizer®)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pearl Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "40 Years to 80 Years"
      },
      "enrollment_count": 237,
      "start_date": "2011-05",
      "completion_date": "2011-11",
      "has_results": true,
      "last_update_posted_date": "2017-01-31",
      "last_synced_at": "2026-09-05T02:27:59.693Z",
      "location_count": 10,
      "location_summary": "Glendale, Arizona • Fullerton, California • Los Angeles, California + 7 more",
      "locations": [
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Pensacola",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01349803"
    }
  ]
}